Clinical Trial Protocol

Protocolized REDUction of non-resuscitation fluids versus usual care in SEptic shock patients. A protocol for the REDUSE randomised clinical trial

Version 1.2

Contents

[1. Trial overview 4](#_Toc154760800)

[2. Background and study rationale 4](#_Toc154760801)

[2.1 Background 4](#_Toc154760802)

[2.3 Previous evidence 5](#_Toc154760803)

[2.4 Rationale for a new trial 5](#_Toc154760804)

[3. Trial hypothesis and outcomes 5](#_Toc154760805)

[3.1 Primary outcome 5](#_Toc154760806)

[3.2 Secondary outcomes 5](#_Toc154760807)

[3.3 Explorative outcomes 6](#_Toc154760808)

[3.4 Rationale for primary and secondary outcomes 6](#_Toc154760809)

[4. Eligibility 7](#_Toc154760810)

[4.1 Inclusion criteria 7](#_Toc154760811)

[4.2 Exclusion Criteria 7](#_Toc154760812)

[4.3. Note on inclusion and exclusion criteria 7](#_Toc154760813)

[4.4 Exit from the trial 8](#_Toc154760814)

[5. Trial design 8](#_Toc154760815)

[5.1 Screening and randomisation 8](#_Toc154760816)

[5.2 Intervention 8](#_Toc154760817)

[5.2.1 The intervention group 8](#_Toc154760818)

[5.2.2 Usual Care arm 9](#_Toc154760819)

[5.3 Follow up 9](#_Toc154760820)

[5.4 Blinding 10](#_Toc154760821)

[5.5 Definitions 10](#_Toc154760822)

[5.5.1. 10](#_Toc154760823)

[5.5.2. 10](#_Toc154760824)

[5.6 Co-enrolment 10](#_Toc154760825)

[6. Data collection 10](#_Toc154760826)

[6.1 Quality control of data 11](#_Toc154760827)

[6.2 Biobank 11](#_Toc154760828)

[7. Ethics and Informed consent 11](#_Toc154760829)

[8. Data management 12](#_Toc154760830)

[8.1 Data handling and record keeping 12](#_Toc154760831)

[8.2 Quality control and quality assurance 12](#_Toc154760832)

[9 Complications 12](#_Toc154760833)

[9.1 Definitions 12](#_Toc154760834)

[9.2 Reporting of complications 13](#_Toc154760835)

[10. Statistical analysis plan 13](#_Toc154760836)

[10.1 Sample size 13](#_Toc154760837)

[10.1.1 Primary outcome 13](#_Toc154760838)

[10.1.2 Secondary outcomes 13](#_Toc154760839)

[10.2 Analysis methods 14](#_Toc154760840)

[10.3 Missing data 14](#_Toc154760841)

[10.4 Subgroup analysis 14](#_Toc154760842)

[10.4 Exploratory analyses 14](#_Toc154760843)

[10.5 Statisticians 15](#_Toc154760844)

[10.6 Data safety monitoring committee 15](#_Toc154760845)

[10.7 Members of the data safety monitoring committee 15](#_Toc154760846)

[10.8 Environmental analysis 15](#_Toc154760847)

[10.9 Health economic analysis 15](#_Toc154760848)

[11. Publication of Data 16](#_Toc154760849)

[11.1 Data sharing 16](#_Toc154760850)

[13. Funding 16](#_Toc154760851)

[14. Timeline 16](#_Toc154760852)

[14.1 One year following the start of the project (end of 2024). 16](#_Toc154760853)

[14.2 Two years following the start of the project (end of 2025). 16](#_Toc154760854)

[14.3 Three years following the start of the project (end of 2026 17](#_Toc154760855)

[14.4 Four years following the start of the project (end of 2027). 17](#_Toc154760856)

[15. Investigators 17](#_Toc154760857)

[15.1 Management group 17](#_Toc154760858)

[15.2 Steering group 17](#_Toc154760859)

[References 17](#_Toc154760860)

[Table 1. Study Schedule 22](#_Toc154760861)

[Appendix A. Description of collected data 23](#_Toc154760862)

[Appendix B. Charter for the Data Safety and Monitoring Committee (DSMC) 29](#_Toc154760863)

[1 Introduction 29](#_Toc154760864)

[2. Primary responsibilities of the DSMC 29](#_Toc154760865)

[D.3 Members of the DSMC 29](#_Toc154760866)

[D 3.1 Members of the DSMC 29](#_Toc154760867)

[D.4 Conflicts of interest 29](#_Toc154760868)

[D.5 Meetings of the DSMC 30](#_Toc154760869)

[D.6 Communication between the steering group and the DSMC 30](#_Toc154760870)

[D.7 Minutes of the DSMC meetings 30](#_Toc154760871)

[D.8 Recommendations to the steering group 30](#_Toc154760872)

[D.9 Statistical monitoring guidelines 30](#_Toc154760873)

[D.10 Conditions for transfer of data from the steering group to the DSMC 31](#_Toc154760874)

[Appendix C. Treatment algorithm for non-resuscitation fluids in the intervention arm. 32](#_Toc154760875)

[Appendix D. Dilution of medications in the intervention group 34](#_Toc154760876)

# 1. Trial overview

The REDUSE trial is a multicentre, investigator-initiated, randomized clinical superiority trial comparing protocolized restrictive strategy for the administration of non-resuscitation fluids with usual care in participants with septic shock. Adult patients with septic shock will be eligible for inclusion. Participants will be randomized within 12 hours of admission to the intensive care unit. Participants will not receive maintenance fluids in the intervention arm unless the total fluid volume is insufficient to provide hydration. All intravenous drugs and nutrition will be concentrated and administered to reduce fluid volume. Resuscitation fluids will be administered according to local routines. The intervention will last for the duration of the intensive care unit stay. Participants in the control arm will receive usual care. The primary outcome will be all-cause mortality at 90 days. Secondary outcomes will be complications during ICU stay, cognitive function, health related quality of life at 6 months, and days alive without mechanical ventilation at 90 days. Healthcare staff involved in the participants' immediate care will not be blinded to the intervention, but participants, outcome assessors, statisticians, manuscript authors and the data safety monitoring committe will be blinded to treatment allocation.

# 2. Background and study rationale

## 2.1 Background

Sepsis is defined as life-threatening organ dysfunction caused by a host response to infection (Singer 2016). Recent estimates suggest that 48 million cases of sepsis occur globally every year and that 11 million sepsis-related deaths occur annually, with the majority of cases occurring in developing countries (Rudd 2020). Septic shock is a subgroup of sepsis with particularly severe circulatory and metabolic abnormalities and approximately 35-50% of patients with septic shock die.

Administration of fluids is an essential component of caring for patients suffering from septic shock. Fluids are administered for different theoretical reasons. Resuscitation fluids are administered intravenously to correct hemodynamic impairment (Rhodes 2016). In contrast, non-resuscitation fluids are administered intravenously and enterally as vehicles for medications and nutrition, to correct electrolyte disturbances, and to ensure adequate hydration (maintenance fluids). The latter purpose is considered to require a total of about 1-2 litres of fluids per day (1 ml/kg/h) in healthy humans and may increase in pathophysiological conditions due to higher than normal losses. More than 50% of patients with septic shock receive 4 L or more of fluids on the first day in the ICU (Marik 2017). This may be adequate in patients with pre-existing deficits, but data suggest that large volumes of fluids are not without risks. Non-randomised studies have indicated that excessive fluid administration might have detrimental adverse effects such as tissue oedema with impaired oxygen delivery and organ function, compartment syndromes and ultimately increased mortality (Boyd 2011, Payen 2008, Silversides 2018, Sakr 2017). This has formed the basis for trials comparing restrictive administration of resuscitation fluids with usual care in adult septic shock patients.

## 2.3 Previous evidence

A recent systematic review with meta-analysis identified 13 trials comparing a restrictive approach of fluid administration with usual care in adult patients with sepsis and/or septic shock (Sivapalan 2023). Twelve of these trials assessed interventions with the objective to reduce administration of only resuscitation fluids. One trial assessed interventions to reduce resuscitation and non-resuscitation fluids (Chen 2015). A meta-analysis of the seven trials including patients with septic shock demonstrated no difference in mortality (RR: 0.97 [97% CI; 0.86-1.09]), but differences in fluid volume between the intervention and control groups were small.

## 2.4 Rationale for a new trial

Based on data showing that non-resuscitation fluids are the major source of fluid after the first day in the ICU we recently performed a feasibility trial comparing a protocolised reduction of non-resuscitation fluids to usual care in septic shock (Lindén-Søndersø 2019,Lindén 2023). Our data shows that this approach may reduce the total volume of administered fluids by a median of 3.6 (95% CI; 1.6 to 5.3) L in the first 3 days after inclusion. This reduction is almost twice as large as the most effective protocol targeting the restriction of resuscitation fluids (Meyhoff 2022). The effectiveness of this approach warrants a trial assessing the effect of protocolized reduction of non-resuscitation fluid administration on patient-important outcomes in septic shock. The fact that non-resuscitation fluids differ in composition and are administered for different indications than resuscitation fluids means that the balance between benefit and harm for the two groups of fluids may differ, further strengthening the argument for such a trial.

# 3. Trial hypothesis and outcomes

The objective is to assess the beneficial and harmful effects of a restrictive strategy for administration of non-resuscitation fluids in adult patients with septic shock.

3.1 Primary outcome

* All-cause mortality at 90 days

## 3.2 Secondary outcomes

* One or more complications in the ICU defined as one or more of the following events in the ICU:

a) Acute cerebral infarction (documented on brain MRI or CT scans) with corresponding neurological symptoms.

b) Acute coronary syndrome (defined as acute myocardial infarction or unstable angina pectoris) AND either reperfusion treatment (percutaneous coronary intervention, PCI or thrombolysis) or initiated/increased antithrombotic treatment.

c) Acute intestinal infarction (either diagnosed during surgery or by angiography).

d) Limb ischemia (defined as clinical signs of limb ischemia AND one of the following treatments: open or percutaneous vascular intervention, amputation, or initiation/increased antithrombotic treatment.

e) New onset severe acute kidney injury (defined as stage 3 according to the kidney disease improving global outcomes (KDIGO) criteria).

* Days alive and free of mechanical ventilation within 90 days of inclusion.
* Cognitive function measured using the Montreal Cognitive Assessment BLIND test (MoCA-BLIND) at 6 months.
* Health-Related Quality of Life using the European Quality of Life visual analogue scale (EQ-VAS) at 6 months.

## 3.3 Explorative outcomes

* Days alive and free of vasopressor therapy within 90 days of inclusion.
* Days alive and free of renal replacement therapy (RRT) within 90-days of inclusion.
* The composite of death at 90-days, new receipt of renal replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value within 90 days)
* Cumulative dose of diuretics during the first 5 days of inclusion (defined daily doses according to the World Health Organization).
* Glasgow Outcome Scale Extended (GOSE) at 6 months.
* European Quality of Life visual 5 dimension-5 level scale (EQ-5D-5L) at 6 months.
* WHO Disability Assessment Schedule (WHODAS) 2.0 (12 item version) at 6 months.
* Modified Fatigue Impact Scale (MFIS) at 6 months.
* All-cause mortality at 12 months.
* Days alive and out of hospital within 90 days of inclusion
* Number of days in the ICU within 90 days of inclusion
* Hypoglycaemia (≤ 3.9 mmol/l) in the ICU
* Hypernatremia (> 159 mmol/L) in the ICU
* Acid base disturbances (hyperchloremic acidosis [pH < 7.15 and plasma Cl- > 115], metabolic alkalosis [pH > 7.59 and S-BE > 9]) in the ICU
* Central venous catheter related complications that could potentially be related to concentrated drugs given in the intervention group (for example, thrombosis, stenosis, malfunction, and infections) in the ICU

For Swedish sites mortality data will be collected from the National board of Health and Welfare.

## 3.4 Rationale for primary and secondary outcomes

Several observational studies have reported an association between a positive cumulative fluid balance and mortality (Boyd 2011, Sakr 2017).

Because less administration of non-resuscitation fluids could decrease intravascular volume and therefore increase ischemia and acute kidney injury we will assess the incidence of ischemic complications and acute kidney injury. Previous trials assessing effects of restrictive administration of resuscitation fluids in sepsis have found no effect or a decreased incidence of acute kidney injury (Douglas 2020, Hjortrup 2016, Meyhoff 2022)

Days alive and free of mechanical ventilation is a patient-important outcome and is also essential to assess potential effects on healthcare costs. Strategies to reduce fluid overload in patients suffering from acute respiratory distress syndrome have been suggested to increase the number of days alive and free of mechanical ventilation (Wiederman 2006).

Cognitive impairment and decreased HRQoL are common after sepsis. Restrictive fluid administration has been associated with both impaired and improved cognitive function in observational studies of patients suffering from acute respiratory distress syndrome (ARDS) (Mikkelsen 2012, Wang 2014). No differences in HRQoL and cognitive function could be demonstrated by restricting resuscitation fluids in septic shock but clinically important differences could not be excluded (Kjær 2023). Based on a modified Delphi process involving patients and researchers (http://www.improvelto.com), the performance-based cognitive screening measure MoCA and the patient-reported outcome measure EQ-5D-5L have been the recommended tests for cognitive function and HRQoL in patients with acute respiratory failure, a common organ failure in septic shock. These tests have been used or are used in several large trials in septic shock and have been translated into many languages including Swedish.

# 4. Eligibility

Patients will be eligible for inclusion if they fulfil all of the inclusion criteria and none of the exclusion criteria.

## 4.1 Inclusion criteria

* Adult (≥ 18 years of age)
* Septic shock according to the Sepsis 3 criteria at any time within 12 hours after ICU admission (suspected or confirmed infection, plasma lactate above 2 mmol/L, and infusion of vasopressor/inotrope to maintain mean arterial pressure of 65mmHg or above after receiving adequate fluid resuscitation [> 1L within 12 h of screening]) and need for vasopressors at the time of screening.

## 4.2 Exclusion Criteria

* Confirmed or suspected pregnancy
* Previous inclusion in the trial
* Screened more than 12 hours after ICU admission.

## 4.3. Note on inclusion and exclusion criteria

Patients with septic shock receive large amounts of fluids and they are the patient category in which an association between a positive fluid balance and a poor outcome has been consistently observed in observational studies. Patients with septic shock have a high mortality and are the most common group of critically ill patients in which large volumes of fluids are administered. Hence, this is a patient group in which the intervention is expected to have the greatest effect.

Patients readmitted to the ICU during the same hospital stay will be allocated to the same study arm to which they were initially allocated regardless of diagnosis. Patients readmitted to the ICU after discharge home will not be eligible for inclusion.

## 4.4 Exit from the trial

A participant or his/her surrogate is free to withdraw from the trial at any time. A participant will exit the trial if the participant withdraws her/his consent. The participant making the withdrawal of consent will be asked for permission to use the data obtained prior to withdrawal and to obtain data for the primary outcome measure. If permission is obtained, the participant will be included in the final analyses. If the participant declines, all data with the exception of initials, sex, gender and date of withdrawal will be destroyed. If the trial intervention is discontinued by the treating physician because of adverse events, if the participant is withdrawn from active care and/or the focus of care is changed to palliation, or any other reason, this does not constitute withdrawal from the trial and the participant will not exit the trial (data collection will continue). A participant transferred to a non-REDUSE ICU will not exit the trial. All participants randomised in this trial will be analysed on an intention-to-treat basis.

# 5. Trial design

The trial is a multicentre, randomised trial with a 1:1 concealed allocation. Participants will receive either protocolized restrictive administration of non-resuscitation fluids or usual care. The trial will be investigator-initiated and non-commercial. The steering group, author group, trial statistician, outcome assessors, prognosticators and the trial coordinating team will be blinded to group allocation. Please see Table 1 for a study schedule.

## 5.1 Screening and randomisation

Clinical investigators at each participating ICU will be responsible for screening of all admitted patients with a diagnosis of septic shock. A screening log will be compiled while the trial is active at each site and will include all adult patients with an admission diagnosis of septic shock whether they are eligible for inclusion or not. We will document reasons for not including an eligible patient. Informed consent will be obtained as specified in each national ethical approval. Trial sites will have access to an internet-based randomisation application within the eCRF to allow for immediate allocation and adequate generation and concealment of the allocation sequence. Each patient will be assigned a unique trial number. Randomisation will be performed with permuted blocks of varying block size unknown to the trial investigators, stratified for trial site.

## 5.2 Intervention

Patients will receive non-resuscitation fluids according to the protocol described below within two hours of randomization. Non-resuscitation fluids are defined as fluids other than colloids, blood products, or crystalloids administered to correct hemodynamic impairment as noted in patients' charts. The type of maintenance fluids will be given according to usual care at each respective centre with the objective to use similar types of fluids in both groups. The allocated treatment will be continued for the duration of the ICU admission in a REDUSE ICU up to a maximum of 90 days. A study subject readmitted to a REDUSE ICU within 90 day of inclusion will continue to receive the allocated treatment.

### 5.2.1 The intervention group

* Maintenance fluids will be discontinued in participants who are positive in cumulative fluid balance and are judged not to be dehydrated by the treating physician.
* Intravenous fluid and enteral water will be given as needed to correct electrolyte disturbances.
* Enteral nutrition will have an energy density of 2 kcal/ml and administered according to local practice.
* Glucose may be used at a maximal dose of 1g/kg/day using 20% or more concentrated glucose solutions starting at 72 h after inclusion as nutrition if enteral feeding is not tolerated. Glucose at this concentration or higher may be started earlier in patients at risk of hypoglycemia (blood glucose <5 mmol/l and trending downwards) and in patients with insulin dependent diabetes if enteral feeding is not tolerated and if local protocol mandates this.
* Parenteral nutrition will be administered according to local protocol.
* The intervention group will receive intravenous medications concentrated according to protocol (Appendix D).
* Patients who are neutral or negative in cumulative fluid balance will receive maintenance fluids and other fluids in a dose that ensures that the total dose of fluids covers the daily need of water (about 1ml/kg/h).

### 5.2.2 Usual Care arm

* The usual care arm will receive type of non-resuscitation fluids according to local routines.
* Maintenance fluids (Crystalloids and/or glucose) will be given at a dose of 1 ml/kg/h unless local protocol states otherwise.
* Glucose solutions will be used at maximal concentration of 10% unless local protocol states otherwise.
* Medications will be concentrated according to local protocol.

Site investigators will establish what constitutes usual care in their ICU prior to initiation of the trial. Site investigators will be responsible for preventing drift in the usual care group. Site principal investigators will continuously monitor treatment in the two groups to ensure compliance with the protocol.

In both groups, resuscitation fluids (albumin, blood products, crystalloids given to correct hemodynamic impairment as noted in patient chart or at a rate of ≥ 5ml/kg/h if indication is unclear) will be administered according to the surviving sepsis campaign guidelines during the salvage and optimisation phases of resuscitation and according to local protocol during the stabilisation and de-escalation phases (Rhodes 2017, De Backer 2022). All other care of patients will be according to local routines and will not be protocolized.

## 5.3 Follow up

At 6 months, a specially trained and blinded outcome assessor will perform a structured telephone interview and administer the MoCA-BLIND, EQ-5D-5L, GOSE, WHODAS and MFIS evaluations. In cases were the participant´s outcome is too poor to complete the tests, a relative or close friend will be asked to rate the participant´s HRQoL by the EQ-5D-5L test. The outcome assessor may be an occupational therapist, a physician, a research nurse, or a psychologist. Outcome assessors will receive a trial manual with detailed guidelines for performing the questionnaires and assessments. Training sessions will be provided by the trial coordinating team. To avoid missing data alternative strategies will be used. These include inviting the participant to visit a clinic, visiting the participants’ home or an audio-visual web-based meeting. If needed an authorized interpreter will be used.

## 5.4 Blinding

The clinical team caring for participants will not be blinded due to the nature of the intervention. The participants and their family will not be actively informed about group allocation. The steering group, author group, trial statistician, outcome assessors, prognosticators, the trial coordinating team, manuscript writers and the data safety and monitoring committee will be blinded to group allocation. The two intervention groups will be coded as "A" and "B". Two conclusions from all outcomes in the main manuscript will be drawn: one assuming "A" is the experimental group and "B" is the control group - and one assuming the opposite. All conclusions must be approved by the author group before the code is broken.

## 5.5 Definitions

5.5.1. Days. Day 1 is from time of randomization to start of new 24 hr period as per local protocol. Day 2 is next 24 hr period. The last day of ICU stay is from the start of new 24 hr period as per local protocol until discharge.

5.5.2. Fluid balance is calculated as sum of all input of enteral and parenteral fluids minus all measured losses. Estimated loss through evaporation will not be included in fluid balance. Stool will not be included in balance unless the patient has a faecal management system or similar device in place.

5.5.3. Protocol deviations include randomization of a non-eligible patient and non-compliance with treatment algorithm in the intervention and control arms as described above.

## 5.6 Co-enrolment

We will encourage co-enrolment with other interventional trials, unless the trial protocols are incompatible. Co-enrolment agreements will be established with the sponsor/principal investigator of such trials and a list of trials approved for co-enrolment will be available to the investigators.

# 6. Data collection

Clinical, laboratory and background data will be collected at the time of enrolment, during the ICU-stay, at ICU-discharge and at follow-up. Data will be obtained from hospital records, and relatives and close friends of the patient, and will be entered into a web-based electronic case report form (eCRF) by site personnel. Data from the web-based forms will be migrated to a trial database, which will be handled by the coordinating team. The sponsor supplies a standard description of all units of measurement in the eCRF. If a trial site uses different units of measurement and this might be a potential source of error, the site investigator should contact the coordinating team to have the data capture module modified. Data not obtainable will be registered as missing and measures to obtain data should not delay intervention or concomitant treatment (i.e. central line not in place at the time of data collection). All efforts will be made to collect data on the primary and secondary outcomes for patients transferred to a non-REDUSE ICU. Fluid data will be collected as long as the patient receives the intervention. A detailed description of data is provided in Appendix A

## 6.1 Quality control of data

Site principal investigators will be responsible for training clinical staff on correctly entering variables into the electronic case report forms (eCRFs). Particular emphasis will be placed on recording fluid administration and fluid balance data in a standardized manner. Instructions will be available in the trial master file and eCRFs. All sites will receive a site initiation visit via a digital meeting from an independent monitor before the start of inclusion. Moreover, monitors will visit all sites when 10 participants have been included. The visits will include control of routines for data collection and entry as well as quality control of data by source data verification. To minimize missing data and ensure adherence to the protocol we will use central monitoring and we will develop a central monitoring plan before the start of the trial. The site investigator must sign all eCRFs before trial completion to verify that the recorded data is correct and complete.

## 6.2 Biobank

We will collect blood samples at 0 hrs, 72 hrs, and 5 days after randomization. At each time point we will collect 12 ml of blood. Blood samples will be processed and aliquoted according to a separate protocol. All samples will be transported to and stored in a central biobank. Samples may be analysed for routine clinical laboratory measurements and prognostic biomarkers, including markers of neuronal injury, inflammation, and mitochondrial content. No analysis will occur before the trial ends, and no results from the biobank will be published in the initial manuscript. Participation in the biobank will be optional for each site.

# 7. Ethics and Informed consent

Ethics applications will be submitted to the National Research Ethics boards of participating countries. The applications will seek approval for a deferred consent process. This is based on the premise that to have the greatest possible impact; the intervention has to be started as soon as possible after admission to the ICU. Because cognitive symptoms are hallmark symptoms of septic shock, we regard it as impossible in most cases to obtain an informed consent at the time of presentation (Singer, 2016). We judge that this strategy is justifiable according to the Declaration of Helsinki article 30 available from the World Medical Association. Surviving participants will be asked for written consent as soon as they are able to make an informed decision. The participants will be provided with written and oral information on this trial to make an informed decision about participation in the trial. A participant who does not give consent will be asked if already collected data can be used. The consent form must be signed by the participant. At Swedish sites, a member of the research team will approach the legal representative or a personal consultee (relative or close friend) as soon as practically possible to inform about the trial and seek their opinion about the participation of the patient in the trial.

# 8. Data management

## 8.1 Data handling and record keeping

Individual patient data will be handled as ordinary chart records and will be kept according to the legislation (e.g. data protection agencies) of each participating country. Data will be entered into web-based electronic case report form (eCRF). The electronic data capture module fulfils criteria for handling of patient data according to the Swedish legislation on management of personal data and will be compliant with the General Data Protection Regulation of the EU (European Parliament and Council of the European Union. Directive 2001/20/EC) and with the Federal Drug Administration’s guidelines for electronic signatures (FDA 21 CFR Part 11 Guidelines for Electronic Signatures). All original records will be retained at trial sites or at the principal investigator for 15 years to allow inspection by relevant authorities. The trial database will be maintained for 15 years.

## 8.2 Quality control and quality assurance

The trial will be externally monitored by national monitoring offices coordinated by the clinical trial manager and Clinical Studies Sweden, Forum South. All variables will be collected in a patient-specific trial ledger or directly in the eCRF. Site principal investigators will be responsible for training clinical staff on how to enter variables correctly. Special emphasis will be given to how to record fluid administration and fluid balance in a standardized manner. Instructions will be available in the trial ledger and in the electronic case report forms (eCRFs). All sites will have a digital site initiation meeting with monitors before start of inclusion and a closeout visit at end of study. Moreover, all sites will be visited by monitors when about 10 participants from that site have been included. The visits will include control of routines for data collection and data entry as well as quality control of data by comparing selected source data with data entered in eCRFs. The site investigators will be responsible for entering all relevant data into the electronic CRFs. The CRFs will be constructed in order to ensure data quality with predefined values and ranges on all data entries. To further optimize completeness and quality of data we will also use central data monitoring. A detailed central data monitoring plan will be developed before inclusion of 400 patients in the trial.

# 9 Complications

Detection, documentation and reporting of complications will be the responsibility of the local investigator.

## 9.1 Definitions

Patients with septic shock in the ICU experience a host of complications. Only a small number of those could be considered to be related to the intervention. In addition to the patient-centered complications described above we will monitor patients for;

* Suspected unexpected serious adverse complications (SUSAC) (an adverse event not reasonably explained by other factors than the intervention which may cause death or be life threatening, prolong hospitalisation or may result in significant disability/incapacity
* Severe hypoglycemia (blood glucose ≤ 2.2 mmol/l)

## 9.2 Reporting of complications

All SUSACs and episodes of severe hypoglycemia observed by the investigator or other caregivers must be recorded in the eCRF. The circumstances of a SUSAC should be described and should be reported to the principal investigator within 48 hrs. The causality between the trial intervention and the SUSAC should be assessed by the local investigator. The local investigator is required to follow each participant with a suspected unexpected serious adverse complication until resolution of symptoms. Reports of a SUSAC will be assessed for safety by a qualified physician in the trial coordinating team (medical monitor). All SUSACs will be reported to the DSMC within 3 day of reaching the steering group.

# 10. Statistical analysis plan

A detailed statistical analysis plan will be published before any data is available for the trial investigators. In short, data will be analysed by two independent statisticians blinded to the treatment on an intention-to-treat basis. The intention-to-treat population is defined as all randomized patients who consented to use of their data. The per-protocol population is defined as all randomized patients fulfilling all inclusion criteria and no exclusion criteria who consented to use of their data, and excluding those having one or more protocol deviations as defined above (5.5.3). Patients will be considered to be included in the trial when they are randomized. A detailed statistical analysis plan will be published before the last participant is randomized.

## 10.1 Sample size

## 10.1.1 Primary outcome

The sample size calculation is based on an expected 90-day mortality of 45 % in the control group (Hjortrup 2016, Perner 2012, Shankar Hari 2016, Hernandez 2019, Holst 2014). To detect an absolute reduction in mortality of 7.5%, with an alfa of 5% and a power of 90% the required sample size is 1808. We chose 7.5% as anticipated intervention effect because it is a realistic and clinically relevant effect size observed in previous large intensive care trials assessing interventions in critically ill patients (Perner 2012, Andersen-Ranberg 2023). To account for loss to follow-up and no-consent from some patients we will include a total of 1850 patients.

## 10.1.2 Secondary outcomes

Power estimation for the MoCA-BLIND score based on a minimal important difference of 1.5, a standard deviation of 2.8, and the above estimated sample size leads to a power of 100%. (Brown 2018).

Power calculation for EQ-VAS score based on a minimal important difference of 5 points and a standard deviation of 20 points and the above estimated sample size leads to a power of 99% (Contrin 2013, Garanja 2004, Hammond 2020, McLure 2018)

Power calculation for days alive and free of mechanical ventilation based on a minimally important difference of 2 days and a standard deviation of 12 leads to a power of 90.4% (Hernandez 2019). The sample size was reduced by 15% to account for the fact that this parameter is not expected to be normally distributed.

The rate of complications in the control group is estimated to be 30% and assuming a relative risk reduction of 20 % to be a minimally important difference, the above estimated sample size leads to a power of 99 % (Meyhoff 2022).

## 10.2 Analysis methods

Analyses will be performed according to an intention-to-treat principle. All analyses will be adjusted for site of admission. The primary outcome will be analysed using mixed effects logistic regression with site as a random intercept. RR will be estimated using the ‘nlcom’ STATA command. Secondary continuous outcomes (MoCA-BLIND and EQ-VAS) will be analysed using mixed effects linear regression with site as a random intercep. Count data (days alive and free of mechanical ventilation and complications) will be analysed using van Elteren test.

All primary conclusions will be based on our primary outcome and, a priori, secondary and exploratory outcome results will be considered as hypothesis generating. Based on this we will not consider a P-value of 0.05 as a threshold for statistical significance for all analyses. for multiple comparisons.

## 10.3 Missing data

Missing data will be handled according to the recommendation by Jakobsen et al. 2017. We anticipate that the proportion of missing values on primary and secondary outcomes other than health-related quality of life and cognitive function will be less than 5%. For health-related quality of life and cognitive function we expect missing data to be less than 15%.

## 10.4 Subgroup analysis

The heterogeneity of the intervention effect on the primary and secondary outcomes will be assessed in subgroups based on baseline characteristics at randomization.

* + Mechanical ventilatory support at the time of randomization (defined as invasive or non-invasive mechanical ventilation or nasal high flow treatment (yes/ no).
  + Acute kidney injury at the time of randomization (≥ KDIGO stage 1 (yes/ no))
  + Gender (male/ female)
  + Age (≥ 65 years; yes/ no)
  + Frailty Clinical frailty scale (≤ 3, 4, >4).
  + Weight at admission (≥ median of the intention to treat population (yes/ no))
  + Validated infection as suggested by a Linder-Mellhammar score ≥ 3 (yes/ no) (Mellhammar 2022)
  + IV fluid at time of randomization < 30 ml/kg (yes/ no)
  + Plasma Lactate (> 4 mmol/l) (yes / no)

## 10.4 Exploratory analyses

We will perform an analysis including only centres in which a median difference in total volume of administered fluid between the groups in is > 3L at day 4. We will also perform a subgroup analysis including only centres in which a median difference in cummulative fluid balance is > 2 L at day 4. Because patients staying longer in the ICU will be exposed to the intervention for a longer time will perform a subgroup analysis of patients staying four days (D1-D4) or more in the ICU.

Because the amount of glucose may differ between the intervention and control groups we will also perform an analysis of the interaction between the amount of intravenous glucose prior to full enteral nutrition or initiation of parenteral nutrition and treatment effect.

## 10.5 Statisticians

Analyses of results will be performed by two independent statisticians.

## 10.6 Data safety monitoring committee

There will be an independent Data Safety Monitoring Committee (DSMC) which will monitor the trial according to the charter for the DSMC (appendix B). The DSMC will arrange with an independent statistician to conduct a blinded interim analysis. The DSMC will be able to request unblinding of data if they find it necessary. The DSMC will be provided with data on survival and can initiate an analysis at any time they request. Lan-DeMets group sequential monitoring boundaries will be used to decide if the trial should be stopped (Lan and Demets, 1983).

## 10.7 Members of the data safety monitoring committee

Todd W. Rice, MD, MSc Associate Professor of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Nashville, TN, USA

Naomi Hammond, PhD RN BN MN (Crit. Care) MPH Senior Research Fellow/ Operations Lead, Critical Care Program Intensive Care Clinical Research Manager, The George Institute for Global Health, Sidney, Australia

Qiang Li, MBiostat BPH AStat, Lead Biostatistician, Biostatistics and Data Science Division  
Stats lead, Global Brain Health Initiative, Conjoint Senior Lecturer, Faculty of Medicine, UNSW and the The George Institute for Global Health Sydney, Australia.

## 10.8 Environmental analysis

We will analyse the effects of the intervention on the climate and the environmental footprints of ICU care for patients with septic shock using life cycle analysis (Boberg 2022). In this analysis, Helsingborg hospital will be used as a base scenario and in sensitivity analyses we will assess the impact of assumptions regarding transportation distances, energy mix and waste handling. The environmental analysis will include an assessment of downstream environmental effects of the intervention on health in the general public as expressed in Disease Adjusted Life Years (DALYs) as detailed in a separate plan.

## 10.9 Health economic analysis

We will analyse health economic aspects of the intervention. A detailed plan for such an analysis will be published before the last participant is randomized.

# 11. Publication of Data

The analysis process will be performed with the allocation code unbroken and with the trial arms only known as A and B. Two abstracts of the main publication will be prepared before the allocation code is broken, with the different arms interchanged (one assuming arm A is the intervention arm, and the other assuming arm B is the intervention arm). All authors must approve both versions before the code is broken. The final main publication will be submitted to a peer-reviewed international journal. Authorship will be granted using the Vancouver definitions and depending on personal involvement and fulfilment of the authors’ respective roles. The author list will include the steering group members, national investigators and additional names. Centres recruiting >30 participants will be entitled to one name, >60 two names, >100 three names, >150 four names, >220 five names in the author list (additional names). After the author list, there will be added: "and the REDUSE-trial group" and a reference to an appendix with all sites, site investigators and the number of participants enrolled. The main publication will report the primary and secondary outcomes. Exploratory outcomes will, due to complexity of reporting be submitted to a peer-reviewed journal in separate manuscripts, as will the studies based on the biobank. Ideas for additional substudies will be presented to the steering group. The steering group will decide which substudies to prioritize. No substudy will be published prior to publication of the main article.

## 11.1 Data sharing

Approximately one year after publication of the main report of this trial individual de-identified data will be available for sharing with researchers who provide a methodologically sound proposal as judged by the steering committee. To gain access, data requestors will need to sign a data access agreement.

**12. Insurance**

When pre-existing insurance is not available, indemnity to meet the potential legal liability of investigators/collaborating hospitals for harm to participants arising from the conduct of the research will be provided by the REDUSE-trial through the sponsor: Region Skåne - Skånevård SUND. The insurance for each country will be specified in each site agreement before the commencement of patient inclusion at that site.

# 13. Funding

The trial will be funded by non-commercial foundations for medical research. Patient recruitment will not commence until there is sufficient funding to allow for inclusion and follow-up of the proposed sample size.

# 14. Timeline

## 14.1 One year following the start of the project (end of 2024).

Run in period by the end of which more than 10 sites should have received training in follow-up evaluations, received a site initiation visit from monitors and started to include patients.

## 14.2 Two years following the start of the project (end of 2025).

- A total of 600 patients should have been included.

- Sites with more than 20 included patients with complete follow up should have received a monitoring visit.


14.3 Three years following the start of the project (end of 2026).

- A total of 1200 patients should have been included by the end of the year

- The interim analysis of the first 400 patients with 90-day outcome data should have been completed.

## 14.4 Four years following the start of the project (end of 2027).

A total of 1850 patients should have been included by the end of the year



# 15. Investigators

## 15.1 Management group

Peter Bentzer, MD, PhD principal investigator

Niklas Nielsen, MD, PhD senior investigator

Janus Christian Jakobsen, MD, PhD chief trialist

Gisela Lilja, OT, PhD, follow-up coordinator

Jane Fisher, PhD, trial Coordinator

Markus Harboe Olsen, MD, PhD, statistical advisor

## 15.2 Steering group

All principal site investigators will be part of the steering group. A representative from the newly formed patient organisation "Sepsisföreningen" will be invited to the management group meetings if/when aspects of the conduct of the trial which are deemed to be of importance from a patient perspective are discussed. Such aspects include any change in the protocol with ethical implications.

# References

Andersen-Ranberg NC, Poulsen LM, Perner A, Wetterslev J, Estrup S, Hästbacka J, et al Haloperidol for the Treatment of Delirium in ICU Patients. N Engl J Med. 2022;387:2425-2435.

Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, Mehta RL; Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009;76:422-7.

Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA: Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011; 39:259-265.

Brown SM, Collingridge DS, Wilson EL, Beesley S, Bose S, Orme J, Jackson J, Hopkins RO.

Preliminary Validation of the Montreal Cognitive Assessment Tool among Sepsis Survivors: A Prospective Pilot Study. Ann Am Thorac Soc. 2018;15:1108-1110.

Chen C, Kollef MH. Targeted Fluid Minimization Following Initial Resuscitation in Septic Shock: A Pilot Study. Chest. 2015; 148: 1462-1469.

Cronhjort M, Bergman M, Joelsson-Alm E, Divander MB, Jerkegren E, Balintescu A, Mårtensson J, Svensen C. Fluid Responsiveness Assessment Using Passive Leg Raising Test to Reduce Fluid Administration and Weight Gain in Patients with Septic Shock. J Anesth Perioper Med. 2017; 4:169-178.

Corl KA, Prodromou M, Merchant RC, Gareen I, Marks S, Banerjee D, Amass T, Abbasi A, Delcompare C, Palmisciano A, Aliotta J, Jay G, Levy MM. The Restrictive IV Fluid Trial in Severe Sepsis and Septic Shock (RIFTS): A Randomized Pilot Study. Crit Care Med. 2019; 47: 951-959.

De Backer D, Cecconi M, Chew MS, Hajjar L, Monnet X, Ospina-Tascón GA, Ostermann M, Pinsky MR, Vincent JL. A plea for personalization of the hemodynamic management of septic shock. Crit Care 2022; 26: 372.

Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, Kaufman DA, Khan A, Levy MM, Martin GS, Sahatjian JA, Seeley E, Self WH, Weingarten JA, Williams M, Hansell DM. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020;158:1431-1445.

Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, et al. Resuscitation fluid use in critically ill adults: an international cross-sectional study in 391 intensive care units. Crit Care. 2010; 14:R185.

Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness. Crit Care 2004;8:R91-8.

Hammond NE, Taylor C, Finfer S, Machado FR, An Y, Billot L, et al. Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: An international cross-sectional study. PLoS One. 2017; 12:e0176292.

Herdman M, Claire Gudex, A Lloyd, MF Janssen, P Kind, D Parkin, Gouke Bonsel, and

Xavier Badia. Development and preliminary testing of the new five-level version of eq-5d

(eq-5d-5l). Quality of life research, 2011; 20:1727–1736,.

Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA. 2019;321:654-664.

Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettilä V, et al. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med. 2016; 42:1695-1705.

Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014; 371: 1381‐1391.

Jakobsen JC, Gluud C, Wetterslev J, Winkel P: When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol 2017, 17:162.

Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17:204.

Kjær MN, Meyhoff TS, Sivapalan P, Granholm A, Hjortrup PB, Madsen MB et al. Long-term effects of restriction of intravenous fluid in adult ICU patients with septic shock. Intensive Care Med. 2023;49:820-830.

Lan G, DeMets D, Discrete Sequential Boundaries for Clinical Trials

Biometrika, 1983, 70; 659-663

Lanspa MJ, Burk RE, Wilson EL, Hirshberg EL, Grissom CK, Brown SM. Echocardiogram-guided resuscitation versus early goal-directed therapy in the treatment of septic shock: a randomized, controlled, feasibility trial. J Intensive Care. 2018, 13;6:50.

Lindén-Søndersø, A., Jungner, M., Spångfors, M. et al. Survey of non-resuscitation fluids administered during septic shock: a multicenter prospective observational study. Ann. Intensive Care. 2019; 9: 132.

Lindén A, Fisher J, Lilja G, Olsen MH, Sjövall F, Jungner M et al . Protocolised reduction of non-resuscitation fluids versus usual care in patients with septic shock (REDUSE): a protocol for a multicentre feasibility trial. BMJ Open. 2023;13:e065392.

Marik PE, Linde-Zwirble WT, Bittner EA, Sahatjian J, Hansell D. Fluid administration in severe sepsis and septic shock, patterns and outcomes: an analysis of a large national database. Intensive Care Med. 2017;43:625-632.

McClure NS, Sayah FA, Ohinmaa A, Johnson JA. Minimally Important Difference of the EQ-5D-5L Index Score in Adults with Type 2 Diabetes. Value Health. 2018;21:1090-1097.

Mellhammar L, Elén S, Ehrhard S, Bouma H, Ninck L, Muntjewerff E, Wünsch D, Bloos F, Malmström E, Linder A. New, Useful Criteria for Assessing the Evidence of Infection in Sepsis Research. Crit Care Explor. 2022;4:e0697.

Meyhoff TS, Møller MH, Hjortrup PB, Cronhjort M, Perner A, Wetterslev J. Lower vs Higher Fluid Volumes During Initial Management of Sepsis: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. Chest 2020;157:1478-1496.

Meyhoff TS, Hjortrup PB, Wetterslev J, Sivapalan P, Laake JH et al. Restriction of Intravenous Fluid in ICU Patients with Septic Shock. N Engl J Med. 2022;386:2459-2470.

Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, et al. The Adult Respiratory Distress Syndrome Cognitive Outcomes Study. American Journal of Respiratory and Critical Care Medicine. 2012; 185:1307–1315.

Needham DM, Sepulveda KA, Dinglas VD, Chessare CM, Friedman LA, Bingham CO 3rd, Turnbull AE. Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study. Am J Respir Crit Care Med. 2017;196:1122-1130.

Nesseler N, Defontaine A, Launey Y, Morcet J, Mallédant Y, Seguin P. Long-term mortality and quality of life after septic shock: a follow-up observational study. Intensive Care Med. 2013;39:881-8.

Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008; 12:R74.

Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus ringer’s acetate in severe sepsis. N Engl J Med. 2012;367:124‐134.

Poukkanen M, Vaara ST, Pettilä V, Kaukonen KM, Korhonen AM, Hovilehto S, Inkinen O, Laru-Sompa R, Kaminski T, Reinikainen M, Lund V, Karlsson S; FINNAKI study group. Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units. Acta Anaesthesiol Scand. 2013;57:863-72.

Richard JC, Bayle F, Bourdin G, Leray V, Debord S, Delannoy B, et al: Preload dependence indices to titrate volume expansion during septic shock: a randomized controlled trial. Crit Care. 2015; 19:5.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017; 43:304-377.

Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.

Sakr Y, Rubatto Birri PN, Kotfis K, Nanchal R, Shah B, Kluge S, et al. Higher fluid balance increases the risk of death from sepsis: results from a large international audit. Crit Care Med. 2017;45:386–94.

Semler MW, Janz DR, Casey JD, Self WH, Rice TW. Conservative Fluid Management After Sepsis Resuscitation: A Pilot Randomized Trial. J Intensive Care Med. 2020;35:1374-1382.

Self WH, Semler MW, Bellomo R, Brown SM, deBoisblanc BP, Exline MC et al. Liberal Versus Restrictive Intravenous Fluid Therapy for Early Septic Shock: Rationale for a Randomized Trial. Ann Emerg Med. 2018; 72: 457-466.

Shapiro NI, Douglas IS, Brower RG, et al. Early restrictive or liberal fluid management for sepsis-induced hypotension. N Engl J Med 2023;388:499–510

Silversides JA, Fitzgerald E, Manickavasagam US, Lapinsky SE, Nisenbaum R, Hemmings N et al. Deresuscitation of patients with iatrogenic fluid overload is associated with reduced mortality in critical illness. Crit Care Med. 2018; 46:1600-1607.

Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810.

Sivapalan P, Ellekjaer KL, Jessen MK, Meyhoff TS, Cronhjort M, Hjortrup PB, Wetterslev J, Granholm A, Møller MH, Perner A. Lower vs Higher Fluid Volumes in Adult Patients With Sepsis: An Updated Systematic Review With Meta-Analysis and Trial Sequential Analysis. Chest. 2023;164:892-912.

Wang L, Long X, Lv M. Effect of different liquid management strategies on the prognosis of acute respiratory distress syndrome. Journal of the Dalian Medical University. 2014; 36: 140–143.

Wiedemann HP, Wheeler AP, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network et al (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–2575

# Table 1. Study Schedule

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Study daya | | | | | | | | |
|  | **1** | **2** | **3** | **4** | **5** | **6- ICU dis.b** | **90** | **180** | **365** |
|  | **ENROLMENT** | | | | | | | | |
| Eligibility assessment | **x** |  |  |  |  |  |  |  |  |
| Informed consent | **x** | **x** | **x** | **x** | **x** | **x** |  |  |  |
| Randomization | **x** |  |  |  |  |  |  |  |  |
|  | **INTERVENTION** | | | | | | | | |
| Protocolized administration of non-resuscitation fluids | **x** | **x** | **x** | **x** | **x** | **x** |  |  |  |
|  | **ASSESSMENT** | | | | | | | | |
| Mortality |  |  |  |  |  |  | **x** |  | **x** |
| Cognitive function |  |  |  |  |  |  |  | **x** |  |
| Health related quality of life |  |  |  |  |  |  |  | **x** |  |
| DAF Mechanical ventilation |  |  |  |  |  |  |  | **x** |  |
| Complications | **x** | **x** | **x** | **x** | **x** | **x** |  |  |  |
| Renal function | **x** | **x** | **x** | **x** | **x** | **x** |  | **x** |  |
| Dose of diuretics | **x** | **x** | **x** | **x** | **x** |  |  |  |  |
| Hemodynamic stability | **x** | **x** | **x** | **x** | **x** |  |  |  |  |
| Glasgow Outcome Scale Extended |  |  |  | **x** |  |  |  | **x** |  |
| WHO Disability Assessment Schedule |  |  |  |  |  |  |  | **x** |  |
| Modified Fatigue Impact Scale |  |  |  |  |  |  |  | **x** |  |
| Safety outcomes | **x** | **x** | **x** | **x** | **x** | **x** |  |  |  |
| Blood sampling | **x** |  |  | **x** |  | **x** |  |  |  |

a) Day 1 one is defined as the day of inclusion and will last until change of day according to local ICU protocol

b) Intervention will only be administered while the patients is in an REDUSE-ICU. If patient is transferred to a non-REDUSE ICU she/he will be considered as discharged from ICU.

DAF = Day alive and free of

# Appendix A. Description of collected data

**During screening**

* Age (years, calculated from date of birth)
* Sex (F/M)
* Lactate (highest value at any time while the patient is in the ICU and receiving vasopressors)
* Date and time of ICU admission (dd-mmm-yyyy, hh:mm)
* Inclusion/exclusion criteria

**Consent information**

- Patient informed (Y/N) and date (dd-mmm-yyyy)

- Reason not informed (if N)

- Patient consented (Y/N)

- Consent withdrawn (Y/N)

- Date of withdrawal (dd-mmm-yyyy)

- Can the data be used (Y/N)

- Can primary outcome be collected (Y/N)

**Background data**

* Height (cm)
* Weight at baseline (kg, standardized according to local practice)
* Clinical Frailty Score
* Baseline creatinine [lowest in the 12 months preceding randomization] (µmol/L)
* Charlson Comorbidity Index
* Type of initial antibiotic treatment
* Suspected pathogen
  + Suspected pathogen sensitive to initial antibiotic treatment (Y/N)
* Hospital admission (dd-mmm-yyyy, hh:mm)
* Hospital location prior to randomization a) Emergency department, b) Operating room, c) Other ICU, d) Other unit
* Surgery prior to inclusion/randomization (Y/N), if yes, specify: a) Head and neck, b) Thorax, c) Abdominal/pelvic, d) Extremities, e) Trauma f) Other
* Origin of sepsis (according to criteria developed by Linder/Mellhammar. Mellhammar et al. Crit Care Exp 2022;4:e0697).

**Baseline variables at study inclusion** (values closest in time to enrolment, within ± 6 h, unless other timeframe is specified)

* Body temperature (degrees Celsius)
* SAPS-3 (Simplified acute physiology score-III)
* Glasgow Coma Score (GCS)
* Creatinine (μmol/L)
* Renal replacement therapy (Y/N)
* Acute renal injury (Y/N, if yes specify KDIGO score)
* Bilirubin (μmol/L)
* Platelet count (x109/ml)
* Mean arterial pressure (mmHg)
* Systolic pressure (mmHg)
* Type of inotropic drug or vasopressor (any dose of dobutamine, dopamine, vasopressin or other V1A agonists, levosimendan, angiotensin II, noradrenaline, adrenaline, milrinone, or other)
* Noradrenaline dose (highest dose in the 6 hours prior to enrollment; μg/kg/min)
* Corticosteroid treatment (Y/N)
* Atrial fibrillation/flutter (Y/N)
* Ischemic events (Y/N) (criteria described above), if yes, specify: a) Limb, b) Cerebral, c) Heart, d) Intestine
* Heart rate (bpm)
* Ventilatory support (nasal catheter, nasal high flow oxygen, Hudson mask or similar, reservoir mask, non-invasive mechanical ventilation, invasive mechanical ventilation [defined as mechanical ventilation through an orotracheal tube or through a tracheostomy], none. Classification at each day will be based on the highest level of support,
* CRP (g/L)
* Leucocytes (x109 cells/L)
* Haemoglobin (g/L)
* Potassium (mmol/L)
* Sodium (mmol/L)
* Chloride (mmol/L)
* Blood glucose (mmol/L)
* FiO2 (%)
* PaO2 (kPa)
* PaCO2 (kPa)
* pH
* Base excess (BE, mEq/L)
* Volume of fluid intake in the 24h prior to inclusion
* Crystalloids (Ringer’s acetate/lactate [ml], 0.9% NaCl [ml], other [ml],
* Colloids (Albumin 4-5% [ml], Albumin 20% [ml], other [ml]
* Blood products (Erythrocytes [ml], Plasma [ml]- Platelets [ml])
* Glucose (any concentration) (ml)
* Parenteral nutrition (ml)
* Enteral nutrition (ml)
* Enteral water (ml)

**Daily from day 1 - 5 after inclusion**

* Resuscitation fluids (Crystalloids administered to correct hemodynamic impairment as noted in the patient chart or given at a rate > 5 ml/kg/h (Ringer’s acetate/lactate [ml], 0.9% NaCl [ml], other [ml]; Colloids (Albumin 4-5% [ml], Albumin 20% [ml], other [ml]; Blood products (Erythrocytes [ml], Plasma [ml], Platelets [ml]).
* Intravenous vehicles and drugs (Antibiotics [mL], Inotropes (includes dobutamine, levosimedan, or dopamine <5mcg/kg/min) [mL], Vasopressors [mL], Analgesics [mL], Sedatives [mL], Insulin [mL] and dose [E/24h], Potassium [mL], Other electrolytes [mL], Other drugs [mL], 5% glucose used as a vehicle [mL], Other concentration of glucose used as a vehicle [mL and concentration in %]).
* Maintenance/replacement and nutrition (Crystalloids administered for reasons other than correcting hemodynamic impairment. If indication in the medical charts is unclear, crystalloids at a rate below 5 ml/kg/h will be classified as maintenance fluids (Ringer’s acetate/lactate [ml], 0.9% NaCl [ml], other (ml), Glucose 2.5% [ml], Glucose 5% [ml], Glucose 10% [ml], Glucose solution 20% (ml), other glucose strength (mL and concentration in %), was glucose given for an allowed indication (on days 1-3 in the restrictive group)
* Parenteral nutrition (ml)
* Enteral nutrition (ml)
* Enteral water (ml)
* Other fluids (mL)
* Total caloric intake [including Propofol and glucose solutions] (kcal)
* Diuretics (Loop diuretics/furosemide [mg/24h], Other (type of drug and mg/24h)
* Fluid output (Urinary output [ml], Drains [ml], Hemorrhage [ml], Faeces [if liquid and collected through a faecal management system, ml], Fluid removal in RRT [ml], Other losses [evaporation excluded] (ml)
* Weight (kg)
* Fluid balance goal for next 24h (Y/N, and volume in mL)
* Creatinine [highest](μmol/L)
* Acute renal injury (Y/N, if yes specify KDIGO score)
* Renal replacement therapy (Y/N)
* Earliest urea (mmol/L)
* Lowest MAP (mmHg)
* Type of inotropic drug or vasopressor (any dose of dobutamine, dopamine, vasopressin or other V1A agonists, levosimendan, angiotensin II, noradrenaline, adrenaline, milrinone, or other)
* Noradrenaline dose (highest dose during the day; μg/kg/min)
* Corticosteroid treatment (Y/N)
* Atrial fibrillation/flutter (Y/N)
* Mechanical ventilation (Y/N)
* Lowest PaO2 (kPa)
* FiO2 (at time of lowest PaO2; %)
* Lactate [highest] (mmol/L)
* Sodium [earliest] (mmol/L)
* Potassium [earliest] (mmol/L)
* Chloride [earliest] (mmol/L)
* Blood glucose [earliest] (mmol/L)
* Ischemic events (Y/N) (criteria described above)
* Safety outcomes (Hypoglycemia [< 3.9 mmol/L] (Y/N), Hypernatriemia [>159 mmol/L] (Y/N), Hyperchloremic acidosis [pH<7.15 and plasma-chloride >115 mmol/L] (Y/N). Metabolic alkalosis [pH>7.59 and base excess >9] (Y/N), Central venous catheter complications (Includes malfunctions, infections, thrombosis and venous stenosis) (Y/N), Suspected unexpected complications (SUSAC) including severe hypoglycemia (Y/N)

**Daily from day 6 to discharge from REDUSE ICU or day 90**

- Patient in a REDUSE ICU this day (Y/N)

- Volume of resuscitation fluids (mL)

- Volume of non-resuscitation fluids (mL)

- Total fluid output (mL):

- Ischemic events (Y/N) (criteria described above), if yes, specify: if yes, specify: a) Limb, b) Cerebral, c) Heart, d) Intestine

- Acute renal injury (Y/N, if yes specify KDIGO score)

* Safety outcomes (Hypoglycemia [< 3.9 mmol/L] (Y/N), Hypernatriemia [>159 mmol/L] (Y/N), Hyperchloremic acidosis [pH<7.15 and plasma-chloride >115 mmol/L] (Y/N). Metabolic alkalosis [pH>7.59 and base excess >9] (Y/N), Central venous catheter complications (Includes malfunctions, infections, thrombosis and venous stenosis) (Y/N), Suspected unexpected complications (SUSAC) including severe hypoglycemia (Y/N)

**At discharge from REDUSE ICU**

- ICU discharge

* Date and time of ICU discharge (dd-mmm-yyyy, hh:mm)
* Status at ICU discharge (alive/deceased)

- Withdrawal of life sustaining therapies (WLST) (Y/N), if yes, specify reason:

* Irreversible organ failure (Y/N); if yes specify Cardiac, Lung, Liver, Kidney, Coagulation, Brain or Other
* Medical comorbidity (Y/N)
* Other (Y/N); specify
* Date and time when WLST decision was made (dd-mmm-yyyy, hh:mm)

**Up to 90 days after inclusion**

* Date of follow-up
* Status (alive/deceased)
* Days alive and free of renal replacement therapy (RRT)
* Days alive and without invasive mechanical ventilation as defined above
* Days alive without vasopressors
* Days alive and out of hospital
* If deceased, date and time of death (dd-mmm-yyyy, hh:mm)

**At 6 months**

* Date of follow-up
* Status (alive/deceased)
* Place of follow up (Institution/ home of patient/ telephone/ digital)
* Montreal Cognitive Assessment (MoCA-BLIND) (face-to-face /digital /telephone)
* Health-Related Quality of Life (HRQoL) using the European Quality of Life visual analogue scale (EQ-VAS). EQ-VAS is a self-report of overall health and part of the EQ - 5 Dimensions 5 Levels (EQ-5D5L) questionnaire and ranges from 0 to 100.
* HRQoL using the EQ-5D-5L questionnaire. EQ-5D-5L assesses HRQoL in five dimensions (mobility, self-care, usual activities, pain, discomfort and anxiety/depression) where each dimension is rated on a five-levels scale.
* World Health Organization Disability Assessment Schedule 2.0 (WHODAS). WHODAS 2.0 is a patient- or proxy-reported measure of disabilities in 12 aspects of daily life. Each question is answered on a five-level scale.
* Glasgow Outcome Scale Extended (GOSE) modified for use after Sepsis. GOSE is a clinician-reported global functional outcome scale with 8 ordinal categories, ranging from dead (1) to upper good recovery (8) based on a structured interview with the patient, proxy (e.g. a relative or close friend) or bot
* Modified Fatigue Impact Scale (MFIS). MFIS is a patient-reported measure of fatigue and consists of 21 questions. Each question is answered on a five-level scale.
* Patient Questionnaire regarding scope, completeness, and timing of follow up. The questions are answered on a five-grade Likert scale or as yes/no
* Background information
  + Does the patient have a native language other than the test language (Y/N)
  + capabilities that may interfere with the patient's ability to perform the tests
    - No problems
    - Hearing
    - Vision
    - Speech problems
    - Dyslexia
    - Paresis
    - Memory problems or other cognitive problems prior to the episode of sepsis
    - Other
  + Known neurological disease
  + Highest education level
    - No formal education
    - Incomplete primary/lower secondary school
    - Complete primary/lower secondary school
    - Incomplete upper secondary school
    - Complete upper secondary school
    - Some university-level education, without degree
    - University-level education, with degree
  + Marital status (married/living together as married, living together with parents/children, or living alone)
  + Current place of residence
    - Home
    - Hospital
    - Rehabilitation centre
    - Nursing home
    - Other
  + Occupational status before the episode of sepsis
    - Working full-time
    - Working part-time
    - Unemployed
    - Retired due to age
    - Retired due to disability / health problems
    - On sick leave
    - Other (e.g. student, housewife)
  + Occupational status at the time of the follow-up
    - Working full-time
    - Working part-time
    - Unemployed
    - Retired due to age
    - Retired due to disability / health problems
    - On sick leave
    - Other (e.g. student, housewife)
    - Date of return-to-work (if applicable)
  + Rehabilitation after the episode of sepsis
    - None
    - Inpatient rehabilitation
    - Outpatient rehabilitation
    - Home-based rehabilitation (community)
    - Physiotherapist only
    - Occupational therapist only
    - Counselling (by e.g. social worker or psychologist)
    - Cognitive Behavioural Therapy
    - Other

# Appendix B. Charter for the Data Safety and Monitoring Committee (DSMC)

## 1. Introduction

The present Charter will define the primary responsibilities of the DSMC, its relationship with other trial components, its membership, and the purpose and timing of its meetings. The Charter will also provide the procedures for ensuring confidentiality and proper communication, and the statistical monitoring guidelines to be implemented by the DSMC.

## 2. Primary responsibilities of the DSMC

The DSMC will, jointly with the steering group, be responsible for safeguarding the interests of trial participants and assessing the safety and efficacy of the interventions during the trial. The DSMC will recommend stopping or continuing the trial to the steering group of the REDUSE-trial. The steering group will be responsible for promptly reviewing the DSMC recommendations, deciding whether to continue or terminate the trial and determining whether amendments to the protocol or changes in trial conduct are required. The DSMC is planned by protocol to meet (physically or online) to evaluate the planned interim analysis of the REDUSE-trial. A statistician selected by the DSMC will perform the interim analyses. The recommendations of the DSMC regarding stopping, continuing or changing the design of the trial should be communicated without delay to the steering group. The steering group has the responsibility to inform, as fast as possible, and no later than 48 hrs., all investigators of the trial and the departments, including patients in the trial, the recommendation of the DSMC and the steering group decision hereof.

## 3. Members of the DSMC

The DSMC is an independent multidisciplinary group consisting of clinicians and a biostatistician that, collectively, has experience in managing ICU patients and in conducting, monitoring and analyzing clinical trials.

### 3.1 Members of the DSMC

Todd W. Rice, MD, MSc Associate Professor of Medicine, Division of Allergy, Pulmonary, and Critical Care Medicine, Nashville, TN, USA

Naomi Hammond, PhD RN BN MN (Crit. Care) MPH Senior Research Fellow/ Operations Lead, Critical Care Program Intensive Care Clinical Research Manager, The George Institute for Global Health, Australia

Qiang Li, Senior biostatistician, The George Institute for Global Health, Sidney, Australia

## 4 Conflicts of interest

DSMC membership has been restricted to individuals free of financial, scientific, or regulatory conflicts of interest. Any DSMC members who develop significant conflicts of interest during the trial should resign from the DSMC. DSMC membership is to be for the duration of the clinical trial. If any members leave the DSMC during the trial, the steering group will appoint the replacement(s).

## 5. Meetings of the DSMC

The members of the DSMC will have one ’Formal Interim Analysis’ meeting to review data relating to treatment efficacy, patient safety, and quality of trial conduct when 90-day follow-up data of 400 patients have been obtained. For details concerning this analysis please see D. 9 and D.10.

Based on the results of this first interim analysis, it is the DSMC’s responsibility to decide if and when additional interim analyses are warranted. The DSMC may additionally meet whenever they decide and contact each other by telephone or e-mail to discuss the evolving information from the trial.

## 6. Communication between the steering group and the DSMC

The DSMC will be blinded in its safety and efficacy data assessments and data transferred to the DSMC will be aggregated according to treatment group and labelled as group A and group B. The DSMC can request unblinding from the steering group. The data transferred from the steering group to the DSMC will be prepared by an independent liaison, with assistance from the trial statistician, in a manner that allows all trial personnel to remain blinded.

The DSMC can request additional reports concerning outcome measures and complications at any time during the trial. The reports should be up-to date should be provided to DSMC within 1 week of the request.

## 7. Minutes of the DSMC meetings

The DSMC will prepare minutes of their meetings. The minutes will describe the proceedings at the meetings, including a listing of recommendations by the DSMC. Because the minutes may contain unblinded information, it is important that they are not made available to anyone outside the DSMC.

## 8. Recommendations to the steering group

After the interim analysis meeting, the DSMC will recommend that the steering group continue, hold or terminate the trial. This recommendation will be based primarily on safety and efficacy considerations and guided by statistical monitoring guidelines defined in this Charter and the trial protocol. Recommendations to amend the protocol or conduct of the trial made by the DSMC will be considered and accepted or rejected by the steering group. The steering group will decide whether to continue, hold or stop the trial based on the DSMC recommendations. The DSMC will be notified of all trial protocol or conduct changes. The DSMC concurrence will be sought on all substantive recommendations, protocol changes, or trial conduct before implementation.

## 9. Statistical monitoring guidelines

The outcome parameters are defined in the REDUSE-trial protocol. For the two groups, the DSMC will evaluate data on:

• The primary outcome measure - all cause mortality at 90 days

• The secondary outcome measures

- Cognitive function measured using the Montreal Cognitive Assessment - BLIND (MoCA-BLIND) at 6 months

- Health-Related Quality of Life using the European Quality of Life visual analogue scale (EQ-VAS) at 6 months.

- Days alive and free of invasive ventilation within 90 days of inclusion.

- Complications in the ICU (cerebral, cardiac, intestinal or limb ischemia or new onset severe AKI).

• Selected exploratory outcomes

- Severe hypoglycemia (≤2.2 mmol/l)

- Hypernatremia (> 159 mmol/L)

- Acid base disturbances (hyperchloremic acidosis [pH < 7.15 and plasma Cl- > 115], Metabolic alkalosis [pH > 7.59 and S-BE > 9]).

- Suspected unexpected serious adverse complications (SUSACs)

- Central venous catheter related complications that could potentially be related to concentrated drugs given in the intervention group (for example, thrombosis, stenosis, malfunction, and infections)

The DSMC will also be provided with these data.

a. Number of patients randomised.

b. Number of patients randomised per intervention group (A, B)

c. Number of patients stratified per site variable per intervention group (A, B)

d. Number of events, according to the outcomes, in the two groups

e. Monitoring reports from respective centers

Based on evaluations of these outcomes, the DSMC will decide if they want further data from the steering group and when next to perform analyses of the data. For the interim analysis, the data will be provided in one file as described below. The DMSC will use Lan-DeMets sequential monitoring boundaries, at the all interim analyses of the primary outcome measure, secondary outcomes. The DSMC will also assess if protocol specified event rates are accurate. If not, the DSMC may suggest an adjustment of trial sample size or duration of follow-up to maintain power. The DSMC should be informed about all SUSACS occurring in the two groups of the trial within 3 days.

## 10. Conditions for transfer of data from the steering group to the DSMC

The DSMC shall be provided with the data described below in one file The DSMC will be

provided with an Excel database containing the data defined as follows:

• Row 1 contains the names of the variables (to be defined below).

• Row 2 to N (where N-1 is the number of patients who have entered the trial) each contains

the data of one patient.

• Column 1 to p (where p is the number of variables to be defined below) each contains in

row 1 the name of a variable and in the next N rows the values of this variable.

The values of the following variables should be included in the database:

A. PtID: a number that uniquely identifies the patient.

B. Rdcode: The randomisation code (group A or B). The DSMC is not to be informed on

what intervention the groups received.

C. 1. EndInd: Primary outcome measure indicator (1 if patient fulfilled the primary outcome

measure at day 90 and 0 if the patient did not).

D. MoCA-BlindInd: Montreal Cognitive Assessment score at 6 months

E. EQ-VASLInd: Health-Related Quality of Life at 6 months

F. DAFInd: Day alive and free of mechanical ventilation

G. ComplicationInd: Complications (1 if patient has had a complication as defined above during ICU stay and 0 if the patient did not).

E. ExplorInd: Exploratorys outcomes as defined above: Exploratory outcomes or SUSACS (1 if patient has had an exploratory outcome (with the exception of severe hypoglycemia) or SUSAC during ICU stay and 0 if the patient did not).

F. GluInd. Severe hypoglycemia as defined above

# Appendix C. Treatment algorithm for non-resuscitation fluids in the intervention arm.

REDUSE/Behandlingsalgoritm/Treatment%20algoritm%20Intervention%20group%20211217.pdf  
a)Administer ONLY in patients where enteral nutrition is not tolerated, earliest start 72 hrs   
 after randomization. Maximum dose 1g/kg/day. Glucose solutions can be used earlier in patients at risk for hypoglycemia (blood glucose < 5 mmol/l and trending downward.

b)Measured ins and outs:   
 Ins: nutrition, maintenance fluids, medications and electrolytes, blood transfusions, colloids.  
 Outs: diuresis, fluid removal from renal replacement therapy, tube drainage, vomiting/gastric tube   
 drainage, bleeding, contents from faecal management system.

c)Overhydrated (increased total body water relative baseline) as suggested by weight above   
 baseline/preadmission body weight, and/or peripheral/radiological oedema

d)Dehydrated (decreased total body water relative baseline) as suggested by body weight below   
 baseline/preadmission body weight, decreased skin turgor and/or dry mucus membranes.

e)Maintenance fluid: intravenous fluid or enteral water prescribed to ensure that total volume of   
 fluid covers basic need of water (approx 1 ml/kg/h).

# Appendix D. Dilution of medications in the intervention group

**MEDICATIONS in the intervention group. The concentrated solutions should only be used once the patient has a central line. To avoid waste of drug, apply protocol when it´s time to change syringe. Glucose may also be supplied as a vehicle for medication rather than a separate infusion of 20% glucose in patients receiving glucose for the indications described in the treatment algorithm (Appendix C). More concentrated solutions than those described below are allowed if already in use at trial site. Drugs not included in the table below should be used in the most concentrated dilution already in use at trial site.**

| **Drug** | **Conc. in stem solution** | **Suggested dilution in intervention group** | **Reference** | **Comments** |
| --- | --- | --- | --- | --- |
| **Suggested dilutions may only be used if patient has a central line** |  |  |  |  |
| **Vasoactive drugs** |  |  |  |  |
| **Adrenaline** | 1 mg/ml | Start at 80 µg/ml and change to 160 µg/ml if infusion rate >10 ml/h | SPC, IM, Micromedex, Halmstad, Borås, UKCPA | **IM;** IV inf 40 - 320 µg/ml, dituted in G.**Halmstad**; 80 µg/ml i NaCl. **UKCPA**; Up to 500ug/ml has been used |
| **Amiodarone (Cordarone, Amiodaron Hameln)** | 50 mg/ml | Dilute to 15mg/ml (20 ml G per 300mg amiodarone)  Note!  Dilute according to local guidelines in cardiac arrest, | SPC, ePED, UKCPA | **SPC**; Dilute in 5% G. **ePed;** 15mg/ml as infusion. **UKCPA**; Many centres infuse daily dose (up to 900mg) in a total volume of 48-50ml |
| **Dobutamine Hameln** | 12,5 mg/ml | 10 mg/ml | SPC, IM, UKCPA | **IM**; Fluid restr. Adult 2 amps (2x20 ml) + 10 ml NaCl/G give 10 mg/ml. |
| **Isoprenaline** | 0,2 mg/ml | use according to local protocol | Micromedex, Gahart´s,  UKCPA | **Halmstad**; 10 ml 0,2 mg/ml in 40 ml G, gives 40 µg/ml. **Micromedex och Gahart´s**; recommend 20 ug/ml for iv bolus and 2 to 4 ug/ml for infusion. |
| **Milrinone** | 1mg/ml | use according to local protocol | SPC | **SPC dilute to 200 ug/ml using G/NaCl.** |
| **Nitroglycerin (Abcur och BioPhausia)** | 1 mg/ml | use according to local protocol | SPC, IM | **SPC**; May be given udiluted using a pump.Can be diluted in G/NaCl. **IM**; 1 mg/ml may be given undiluted |
| **Noradrenaline (Abcur, Pfizer)** | 1 mg/ml | Start at 80 µg/ml and change to 160 µg/ml if infusion rate >10 ml/h | SPC, IM, Micromedex, Stabilis | **SPC**; Noradrenaline 1 mg/ml should be diluted with, G/NaCl before use. **IM**; 160 µg/ml. **Micromedex**; G may protect against oxidation. **Stabilis**; 0.5 mg/ml Norepinephrine bitartrate is stabile in G for 48 h at 20-25 °C. |
| **Levosimendan** | 2.5 mg/ml | 0.05 mg/ml (10 ml levosimendan 2,5 mg/ml in 500 ml G | SPC 161214, IM |  |
| **Phenylefrine (Abcur och Unimedic)** | 0.1 mg/ml | use according to local protocol | Micromedex, IM | **Micromedex**; for iv bolus use 100 µg/ml and 20 µg/ml for inf. |
| **Vasopressin/ Argipressin (Empressin)** | 20 IE/ml | 0.4 E/ml | IM, UKCPA | **IM;** 1 amp. (1 ml, 20 units in 50 ml med G, will give conc 0.4 units/ml. **Gahart´s; 1 E/ml** |
| **Antibiotiotics** |  |  |  |  |
| **Acyklovir** | 25mg/ml | 25 mg/ml | SPC, UKCPA | **UKCPA;** 25mg/ml over 1 hour by controlled rate infusion. If diluted 5mg/ml infused over at least 1 hour**. SPC; Baxter** Aciclovir 25 mg/ml concentrate for solution for infusion may be administered by a controlled-rate infusion pump. |
| **Ampicillin** |  | 1 g in 10 ml of sterile water  2 g in 20 ml of sterile water | SPC, Micromedex | **SPC;** For iv inj. 10 and 20 ml for 1 and 2 g, respectively. **Micromedex;** 1 and 2 g may be diluted in 7.4 and 14.8 ml sterile water, respectively and given in 10-15 min tom minimize risk of seiziures. **Meda/Mylan**. Give slowly (minimum 3-4 minutes). |
| **Anidulafungin** |  | 100 mg in 30 ml of sterile water and add to 100 ml G/NaCl. | SPC, Stabilis, Micromedex, Gahart´s | Infusion rate 1,4 ml/min resulting a total infusion time of 90 min. |
| **Bensylpenicillin** |  | 1 g in 10 ml of sterile water  3 g in 20 ml of sterile water | SPC, IM | **SPC; dissolve** 1 g in 10 ml of sterile water and 3 g in 20-40 ml of sterile water. **IM;** 600 mg in 4-10 ml. Inject slowly (> 3-5 minuter) |
| **Caspofungin (Cancidas)** | 50 mg  70mg | Carefully dissolve 50 mg in 10,5 ml of sterile water. Add to 100 ml NaCl.  Carefully dissolve 70 mg l in 10,5 ml of sterile water. Add to 140 ml NaCl | Micromedex, SPC, IM | Give drug during at least 60 min! |
| **Cefotaxim (Sandoz, Stragen, Villerton)** |  | 1 g in 4 ml sterile water  2 g in 10 ml sterile water | SPC | **SPC Sandoz**;Note that rapid injection of cefotaxim in central line has been reported to cause life threatening arythmia in rare cases. |
| **Ceftazidim (Fortum)** |  | 1 g in 10 ml of sterile water  2 g in 10 ml of sterile water | SPC, IM, Micromedex |  |
| **Ceftriaxon (Fresenius Kabi)** |  | 1 g in 10 ml of sterile water  2 g in 20 ml of sterile water | SPC , Stabilis, SPC Stragen, IM. Micromedex | **Fresenius Kabi**, Use NaCl or G for 2 g. **Stabilis;** 100 mg/ml in water is ok. **Micromedex;** 2 g in 10 ml. **IM;** Infusion if dose ≥ 2 g. |
| **Cefuroxim (C.Stragen och Zinacef)** |  | 750 mg in 6 ml of sterile water  1,5 g in 15 ml of sterile water | SPC, IM |  |
| **Clindamycin (Dalacin)** | 150 mg/ml | 600 mg in 50 ml G/NaCl (gives 11 mg/ml) | SPC, IM | **IM;** Final concentration max 18 mg/ml. **SPC, IM;** shortest infusion time is 600 mg in 20 min. |
| **Cloxacillin (C. Stragen)** |  | 1 g in 20 ml of sterile water  2 g in 40 ml of sterile vatten | SPC | **Stabilis** konc up to 250 mg/ml are ok. |
| **Doxycyklin (Doxyferm)** | 20 mg/ml | 100 mg in 100 ml G/NaCl  200 mg in 200 ml G/NaCl | SPC |  |
| **Erytromycin** |  | 1 g in 20 ml sterile water and add 80 NaCl. | IM, ePed, SPC, | **IM**; Final concentration should not be greater than 10 mg/ml. **ePed;** Give dose in > 1h to mimimize risk of arythmias. |
| **Gentamycin (Gensumycin** | 40 mg/ml | May be given undiluted as bolus.  Repeated doses either diluted or as boluses over 3-5 minutes depending on dosing regimen. | SPC, UKCPA | **SPC**; If adminstered twice daily gantamycin may be given undiluted in 3-5 minutes. **UKCPA**; For large doses ie most centres dilute with 50 ml G/NaCl. |
| **Imipenem/Cilastatin (Tienam, I/C Fresenius Kabi)** |  | 500/500 mg in 10 ml NaCl and add to 90 ml NaCl/G. Maximum concentration of imipenem 5 mg/ml | IM, SPC, UKCPA | **SPC;** doses ≤ 500 mg/500 mg should be given over 20 to 30 minuter and doses >500 mg/500 mg should be given over 40 to 60 minuter. |
| **Meropenem** |  | For bolus dilute in sterile water to a final concentration of 100mg/ml  For infusion dilute to 20mg/ml with NaCl | IM, SPC, UKCPA | **IM;** 0.5-1 g doses in 5 min. 2 g doses in 15-30 min. **SPC**. Meropenem diluted to 20mg/ml in NaCl stable for 3 h in room temperature. |
| **Metronidazol Braun** | 5 mg/ml | Undiluted |  |  |
| **Piperacillin/Tazobactam** |  | 2/0,25 g in 10 ml of sterile water/NaCl  4/0,5 g in 20 ml of sterile water/NaCl  For infusions dilute further with G/NaCl to 50ml | SPC, IM, |  |
| **Tobramycine (Nebcina)** | 40 mg/ml | Use undiluted | IM, SPC |  |
| **Tobramycine (Nebcina)** | 80 mg/ml | 80 mg/ml dilute with 50 ml G/NaCl | SPC | **SPC;** shorter infusion time than 20 minutes will increase risk for toxic side-effects and is not recommended. |
| **Trimetoprim/Sulfametoxazol (Eusaprim)** | 16+80 mg/ml (5 ml/amps) | 2 amps. in 150 ml G.  Observe carefully for precipitates.  4 amps. in 300 ml G | SPC, IM (Co-trimoxazole) | **SPC;** Stable for 2 h! **IM;** possible to give undiluted stock solution in 60-90 min (off label). |
| **Vancomycin (Orion)** |  | 500 mg in 10 ml sterile water. Add to 40 ml NaCl/G to give a conc. of 10 mg/ml  1 g in 20 ml of sterile water. Add to 80 ml NaCl/G to give a conc. of 10 mg/ml | IM, UKCPA | **IM;** In exceptional circumstances 20 mg/ml may be given via a central line. **UKCPA;** 10mg/ml is a commonly used dilution. 20mg/ml has been used in some centers. **IM;** give in 1 h. **Regional dilution routine;** Give a dose of500 mg in 60 min and 1g in a 100 min. |
| **Vorikonazole (Vfend)** | 200 mg | 200 mg in 19 ml of sterile water to a conc. of 10 mg/ml. For doses 50-500 mg: add to 100 ml G/NaCl. For doses > 500 mg: add to 250 ml G/NaCl. | IM, SPC | Final concentration should be 0,5-5,0 mg/ml. Max infusion rate is 3 mg/kg/h. |
| **Fluconazol** | 2 mg/ml | Use undiluted | SPC | Infusion rate 10 ml/min or lower. |
| **Other drugs** |  |  |  |  |
| **Clonidine (Catapresan)** | 150 µg/ml (1 ml ampull) | 30 µg/ml | SPC, IM, UKCPA | **UKCPA;** 6-50 micrograms/ml infusion.  Diluent: Sodium chloride 0.9% or glucose 5%. |
| **Dexdmedetomidine** | 100ug/ml | 8ug/ml | SPC |  |
| **Sodium glycerophosphate (Glycophos)** | 1 mmol/ml | 0.5 mmol/ml  20 ml sodium glycerophosphate 1mmol/ml in 20 ml NaCl. | ePED | **ePED**; Administer in no less than 8 h. |
| **Insulin, humant (Humulin Regular, Actrapid)** | Insulin, humant (Humulin Regular) | 1 E /ml | Stabilis | **Stabilis;** Dilute in NaCl |
| **Levetiracetam** | 100 mg/ml (5 ml flaska) | 250-1500 mg in 100 ml NaCl/G, ges på 15 min. | SPC, IM, Micromedex, Gahart´s | **Micromedex;** Do not exceed a final max cons of 15 mg/ml. Can be given as iv bolus, 3-5 min and cont infusion 200-400 mg/h. |
| **Magnesium sulphate (**Addex-Mg) | 1 mmol/ml | 0.5 mmol/ml, (20 ml in 20 ml NaCl, giving a conc. 0,5 mmol/ml). Give in no less than 10 min. | IM, Gahart´s, VGR guideline, UKAP | **Gahart´s;** D5W and NS are the most common diluents. **UKCPA**; suggested dilutions 1-2mmol/ml |
| **Potassiumhydroxide/** **Potassium phosphate**  **(Addex-Kalium)** | 2 mmol/ml | 1-2 mmol/ml dilute in NaCl if needed | SPC | **SPC;** Give at most 20 mmol potassium/h. |
| **Potassium Chloride** | 2 mmol/ml | 1-2 mmol/ml, in NaCl dilute if needed | SPC | **SPC;** Give at most 20 mmol potassium/h. |
| **Propofol (Propofol-Lipuro)** | 10 or 20 mg/ml | 20 mg/ml for infusion.  According to local routine for intubation | SPC |  |

**NaCl** = Sodiumchloride 9 mg/ml = NS, **G=**Glukose 50 mg/ml=Dextrose 5%=D5W

**IM** = UCL Hospitals Injectable Medicines Administration Guide: Pharmacy Department, 3rd Edition, University College London Hospitals, ISBN: 978-1-405-19192-0, **Gahart´s** = Gahart´s 2021 intravenous medication via https://www.clinicalkey.com. **Micromedex** = https://www.micromedexsolutions.com, **Halmstad** = vårdriktlinje "Inotropa läkemedel och vasopressorer HSH" published in 200913, **Regional dilution routine Region Skåne, Sweden** = www.lakemedelshantering.se, **Stabilis** = https://www.stabilis.org, **UKCPA** = United Kingdom Clinical Pharmacy Assciation, Minimum infusion volumes for fluid restricted critically ill patients, v 4.4 2012